Relmada Therapeutics Inc (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced yesterday that the company has completed dosing of the last patient with REL-1017 (dextromethadone) in the company's double-blind, placebo-controlled Phase 2 clinical study assessing the safety and efficacy of REL-1017.

The product is an adjunctive treatment in patients affected by treatment-resistant depression. The company is likely to reveal top-line results from the study in the third quarter of 2019.

REL-1017 is an orally administered NMDA receptor (NMDAR) antagonist indicated to be active on the NMDAR ketamine binding site. The phase two study is a multicentre, randomised, double-blind, placebo-controlled three-arm study to evaluate the safety and tolerability of multiple oral doses of REL-1017 25mg and 50mg as adjunctive therapy in the treatment of patients diagnosed with major depressive disorder.